Sabitlenmiş Tweet
Glein Sayat 🫀
2K posts

Glein Sayat 🫀
@CardioSayat
Cardiologist-Echocardiographer • First Generation Filipino MD • Into Sports and Fitness • Autism Advocate • Green Thumb
Lipa City, Calabarzon Katılım Kasım 2019
900 Takip Edilen1.3K Takipçiler
Glein Sayat 🫀 retweetledi

#SciFeature 𝗧𝗛𝗘 𝗣𝗛𝗜𝗟𝗜𝗣𝗣𝗜𝗡𝗘𝗦 𝗜𝗦 𝗡𝗢𝗧 𝗔 𝗦𝗠𝗔𝗟𝗟 𝗖𝗢𝗨𝗡𝗧𝗥𝗬 🇵🇭
At first glance, the Philippines may seem small on a world map, but appearances can be misleading. With over 300,000 km² of land spread across its islands, the country is actually larger than many assume.
This misconception largely comes from the Mercator projection, one of the most commonly used map styles. While it preserves shape and direction, making it useful for navigation, it significantly distorts size. Areas near the poles appear much larger, while countries closer to the equator, like the Philippines, are minimized.
Because of this, places like Greenland often look enormous, sometimes comparable to Africa, when in reality, it spans about 2.1 million km², roughly seven times the size of the Philippines, not dramatically larger as maps may suggest. Meanwhile, the Philippines even exceeds the land area of the United Kingdom, which measures around 243,000 km².
Maps help us understand the world, but they don’t always tell the full story. Recognizing how projections influence what we see allows us to better interpret global size and scale, and appreciate the Philippines for its true geographic extent. #Philippines #map #cartography

English
Glein Sayat 🫀 retweetledi

Join me at New Horizons in Dyslipidaemia 2026! Find out more at newhorizonsindyslipidaemia.com/2026 #NHDCongress2026
English

1 year na pala to HAHAHAHA
HAAAY New Year pa din 😂😅😂
Glein Sayat 🫀@CardioSayat
Ung Ate ko bumili online ng New Year decor, sa halip na Happy New Year e naging Haaay New Year.. Randam ko ung frustration ng gumawa nito. Hahaha
Filipino
Glein Sayat 🫀 retweetledi

New Lancet data on GLP-1 agonists 👇
A new paper in The Lancet eClinicalMedicine shows that when GLP-1 therapy is stopped, most people regain the lost weight and lose metabolic benefits. In practice, this means GLP-1s function as chronic, often lifelong therapy not a temporary fix.
To be clear, GLP-1 agonists are improving the health of many people, especially patients with obesity, type 2 diabetes and high cardiometabolic risk. For these individuals, weight loss can be genuinely life-changing.
The concern is not appropriate medical use but indiscriminate use. With millions already taking these drugs and numbers rising rapidly (specially with the new pill format), many users are not patients in the classical sense, but generally healthy or mildly overweight individuals. In this context, the risk–benefit balance changes. Once started, most users will need to stay on GLP-1s indefinitely or face significant rebound effects, often returning to baseline or worse.
As an important caveat: GLP-1s improve metabolic control, but they do not rebuild metabolic capacity. Without resistance training, meaningful metabolic work (Zone 2 and above), and adequate protein intake, long-term use may promote lean mass loss, low energy flux and increased frailty risk with aging.
In addition, we still lack long-term data on potential pancreatic, thyroid, and central neurotransmitter effects.
GLP-1s are powerful tools, but not a standalone solution. Long-term success requires pairing pharmacology with training and metabolic resilience.
IMHO: based on current clinical and research evidence, it is now urgent that clinicians clearly inform users that starting GLP-1 therapy likely means committing to long-term or lifelong use, with all the consequences that may entail.
thelancet.com/journals/eclin…
English




